Which statement about IVIG risk is described in the material?

Which statement about IVIG risk is described in the material?

• A. Cost
• B. Does not increase infection risk
• C. BBW: Thromboembolic event, AKI
• D. Does not target underlying pathophysiology

Answer: (A)

The main concept here is recognizing what kind of risk IVIG was described as having in the material. The material emphasizes the financial and access-related burden of IVIG therapy, so the risk highlighted is cost. IVIG tends to be expensive, with ongoing treatment needing frequent dosing, specialty administration, and variable insurance coverage, which creates a real risk to patients’ ability to start or continue therapy. While there are known safety concerns with IVIG—such as potential thromboembolic events and acute kidney injury (BBW) and the general consideration of infection risk with plasma-derived products—these are separate safety issues and are not the risk described in the material for this question. The option about not targeting underlying pathophysiology touches on mechanism rather than risk and is not the focus of the described risk.

The main concept here is recognizing what kind of risk IVIG was described as having in the material. The material emphasizes the financial and access-related burden of IVIG therapy, so the risk highlighted is cost. IVIG tends to be expensive, with ongoing treatment needing frequent dosing, specialty administration, and variable insurance coverage, which creates a real risk to patients’ ability to start or continue therapy.

While there are known safety concerns with IVIG—such as potential thromboembolic events and acute kidney injury (BBW) and the general consideration of infection risk with plasma-derived products—these are separate safety issues and are not the risk described in the material for this question. The option about not targeting underlying pathophysiology touches on mechanism rather than risk and is not the focus of the described risk.